| Daniel Berton Ahlberg, MD | |
|
4440 Tyrol Crst, Golden Valley, MN 55416-3554 | |
| (763) 427-8547 | |
| (763) 576-5394 |
| Full Name | Daniel Berton Ahlberg |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 4440 Tyrol Crst, Golden Valley, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972556504 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 19682 (Minnesota) | Primary |
| Entity Name | Twin Cities Neurosurgery Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780625491 PECOS PAC ID: 6901801620 Enrollment ID: O20061002000011 |
News Archive
Today's headlines include reports about the final round of polls, forecasts regarding which party will control the House and Senate and analysis of how campaign-trail messages have been playing during the election season's final hours.
The U.S. Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's disease raises at least three major ethical issues that need to be addressed, states a new article in the Hastings Center Report:
Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.
Experts at the University are studying an illness known as HAPE (high altitude pulmonary oedema), which causes fluid to build up in the lungs can and can occur from as low as 2,500 metres, affecting people of all age groups and fitness levels.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Berton Ahlberg, MD 4440 Tyrol Crst, Golden Valley, MN 55416-3554 Ph: (763) 427-8547 | Daniel Berton Ahlberg, MD 4440 Tyrol Crst, Golden Valley, MN 55416-3554 Ph: (763) 427-8547 |
News Archive
Today's headlines include reports about the final round of polls, forecasts regarding which party will control the House and Senate and analysis of how campaign-trail messages have been playing during the election season's final hours.
The U.S. Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's disease raises at least three major ethical issues that need to be addressed, states a new article in the Hastings Center Report:
Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.
Experts at the University are studying an illness known as HAPE (high altitude pulmonary oedema), which causes fluid to build up in the lungs can and can occur from as low as 2,500 metres, affecting people of all age groups and fitness levels.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
› Verified 7 days ago
Dr. Uzma Samadani, MD, PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4225 Golden Valley Rd, Golden Valley, MN 55422 Phone: 763-588-0661 |